376 patients previously treated with the injectable GLP-1s semaglutide and tirzepatide for 72 weeks were transferred onto orforglipron (Foundayo) pills or a placebo for a year Those whod previously been on tirzepatide kept off 75% of the weight theyd lost compared with 49% in the placebo group, and those whod been on semaglutide kept off 79% of the weight compared with 38% in the placebo group Orforglipron (Foundayo) is the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions It was a randomised, double-blind and placebo-controlled study
Available from: Sjstrm L, Narbro K, Sjstrm CD, et al
The dual-action approach of tirzepatide sets it apart from other GLP-1 drugs like Ozempic/Wegovy, and for many individuals it can break through weight loss plateaus
Last updated: 31/10/2025 HOW ITS COMPONENTS WORK: A strong antioxidant and detoxifying preparation consisting of L-glutathione reduced (GSH), N-acetylcysteine, grape extract, D-alpha tocopheryle acetate (Vitamin E) and L-lysine
Personalized perioperative planning is essential for patients on GLP-1RAs
Reported side effects include: Bloating, gas, abdominal cramps